Original InvestigationProspective Validation of the 0/1-h Algorithm for Early Diagnosis of Myocardial Infarction
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
The APACE study was supported by research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the European Union, the Stiftung für kardiovaskuläre Forschung Basel; Abbott, Beckman Coulter, Biomerieux, Brahms, Roche, Siemens, and Singulex. The BACC study was supported by the German Center of Cardiovascular Research and an unrestricted grant from Abbott Diagnostics. The investigated high-sensitivity cardiac troponin T and I assays were partly donated by Roche and Abbott, who had no role in the design of the study, the analysis of the data, the preparation of the manuscript, or the decision to submit the manuscript for publication. Dr. Twerenbold has received research support from the Swiss National Science Foundation (P300PB_167803), the Swiss Heart Foundation, the University Hospital of Basel, the University of Basel, and the Cardiovascular Research Foundation Basel; and speaker honoraria/consulting honoraria from Roche Diagnostics, Abbott Diagnostics, Siemens, Singulex, Thermo Scientific, and Brahms. Dr. Neumann was supported by a grant from the German Heart Foundation/German Foundation of Heart Research and the Else Kröner Fresenius Stiftung; and has received consulting honoraria from Acarix. Dr. Rubini Giménez has received speaker honoraria from Abbott. Dr. Boeddinghaus has received speaker honoraria/consulting honoraria from Siemens. Dr. Wildi has received research funding from FAG Basel and the Gottfried and Julia Bangerter-Rhyner Foundation. Dr. Reichlin has received research grants from the Goldschmidt-Jacobson-Foundation, the Swiss National Science Foundation (PASMP3-136995), the Swiss Heart Foundation, the Professor Max Cloëtta Foundation, the Uniscientia Foundation Vaduz, the University of Basel, and the Department of Internal Medicine, University Hospital Basel; and has received speaker honoraria from Brahms and Roche. Dr. Blankenberg has received research funding from Abbott Diagnostics, Bayer, Boehringer Ingelheim, Siemens, Singulex, and Thermo Fisher; has received consulting honoraria from Bayer, Thermo Fisher, Roche Diagnostics, and Novartis; has received speaker honoraria from Abbott Diagnostics, Bayer, Boehringer Ingelheim, Siemens, Thermo Fisher, AstraZeneca, Medtronic, Pfizer, and Roche Diagnostics; and has served on advisory boards for Bayer, Boehringer Ingelheim, Thermo Fisher, Roche Diagnostics, and Novartis. Dr. Mueller has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the European Union, the Stiftung für Kardiovaskuläre Forschung Basel, Abbott, Alere, AstraZeneca, Beckman Coulter, Biomerieux, Brahms, Roche, Siemens, Singulex, Sphingotec, and the Department of Internal Medicine, University Hospital Basel; and has received speakers/consulting honoraria from Abbott, Alere, AstraZeneca, Biomerieux, Boehringer Ingelheim, BMS, Brahms, Cardiorentis, Novartis, Roche, Siemens, and Singulex. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The hs-cTnI and hs-cTnT assays were donated by Roche and Abbott, who had no role in the design of the study, the analysis of the data, the preparation of the manuscript, or the decision to submit the manuscript for publication.
- ∗
Drs. Twerenbold and Neumann have contributed equally to this work and should be considered first authors.
- †
Drs. Westermann and Mueller have contributed equally to this work and should be considered senior authors.